• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

A roadmap to preserving the prime years of patients diagnosed with MacTel


According to Thomas Aaberg, MR, the novel therapy is geared to treat rare, debilitating eye disease.

Developing technology is offering hope to patients diagnosed with macular telangiectasia.

Developing technology is offering hope to patients diagnosed with macular telangiectasia.

Serving as chief medical officer at Neurotech Pharmaceuticals, I get to be on the front lines and witness some of the company’s latest innovations, including the latest biotechnological advancement: an encapsulated cell therapy (ECT) for the treatment of macular telangiectasia, or MacTel.

The challenge

MacTel is a bilateral, degenerative eye condition defined by progressive loss of the neurosensory retina adjacent to and ultimately involving the fovea. An age-progressive condition, with no known cause, it shows no preference based on gender, ethnicity, occupation, or any other known factor.

Initially, the disease was thought to be a vascular disorder of the retina. However, the most recent research suggests that MacTel is a disease of the Müller glial cells, which support and maintain the integrity and health of the retina. It appears that as Müller cells die off, photoreceptors and other retinal neurons go with them. Changes in retinal vascularity are a secondary result of the disease.

Patients with MacTel typically experience the first symptoms in their 50s or 60s, though the condition has likely been progressing for many years, even decades. The slow progression of MacTel results in the loss of about 1 letter of the Snellen visual acuity each year.

Early on in the disease process, patients experience the development of paracentral scotomas, or blind spots, that are most noticeable during activities such as reading. Their reading speed typically slows as letters and words fall into the scotomas and disappear from their visual field. Driving often becomes a source of anxiety, as patients lose confidence in their ability to see vehicles and other road hazards that enter their blind spots.

With further progression, the paracentral scotomas become central. Patients progressively lose visual acuity and visual tasks become increasingly difficult. In some cases, vision can deteriorate to 20/200.

Figure 1

Figure 1


Before the development of optical coherence tomography (OCT), MacTel was diagnosed by clinical exam and fluorescein angiography. Typical clinical characteristics include a subtle grayish change to the temporal parafoveal region, the presence of crystal deposits, pigmentary changes, and right-angled vessels. Angiographic findings demonstrate the namesake bilateral juxtafoveal vascular telangiectasia, and associated late fluorescein leakage (Image 1).

With the advent of OCT machines, we have been able to see other nearly pathognomonic findings such as cavitary changes in the parafoveal region (which are likely areas where the Müller cells and photoreceptors have atrophied) and breaks in the ellipsoid zone (Image 2). In more advanced cases of MacTel, intra- and subretinal neovascularization develop with associated subretinal and intraretinal fluid.

Figure 2

Figure 2

Treatment attempts

To arrest the progression of MacTel, clinicians have tried intraocular steroids and anti-VEGF drugs, but these therapies do not produce a durable response. The anti-VEGF drugs and/or careful focal laser photocoagulation have been shown to stop the neovascular complications, but neither alter the underlying disease process. In short, no approved treatment exists for MacTel.

The potential of ECT and CNTF

One of the principal jobs of Müller glial cells is to produce CNTF, which in turn supports the normal function of photoreceptors and is a powerful neuroprotector. It has been shown in mouse models that depleting these Müller glial cells leads to a loss of photoreceptors, development of vascular telangiectasia, breakdown of the blood-retinal barrier, and subsequent neovascularization. This process exactly mimics MacTel in humans.

Reintroducing CNTF to these mice models arrests some of these processes. It slows the loss of photoreceptors and the resulting downstream effects. The problem with CNTF as a therapy is that its half-life is just minutes long, so it must be constantly produced within the eye.

Consequently, unlike other injectable retinal therapies that require administering a drug once a month or at some reasonably prescribed frequency, CNTF would need to be injected daily or even many times a day. This is simply not feasible, but the goal for continuous production of CNTF led to the development of Neurotech’s ECT and the NT-501 device. 

ECT utilizes an implantable device containing engineered human retinal pigment epithelium cells that are transfected with modified DNA plasmid. The sole job of that DNA plasmid is to direct the cells to produce a drug, protein, or peptide that is ultimately therapeutic. It is essentially like implanting a small drug factory or bioreactor directly into the eye. The NT-501 device can produce and release neuroprotective CNTF continuously, exactly where it is needed.

NT-501 cutaway. (Images courtesy of Thomas Aaberg, MD)

NT-501 cutaway. (Images courtesy of Thomas Aaberg, MD)

NT-501 (Figure 3) is about the size of a grain of rice, and once it is surgically implanted, patients cannot see or feel it. The pores in the device’s casing are precisely sized to allow nutrients to flow in and CNTF to flow out, but they block the patient’s immune system from seeing the drug-producing cells within. So far, this approach has proved exceptionally safe under intensive testing.

We are currently undertaking a phase 3A and 3B study and a bilateral study specific to MacTel. The trials are projected to be completed in the fourth quarter of 2022, and if the results are positive a product license application will be submitted for FDA evaluation.

NT-501 is also being tested for glaucoma therapy in an investigator-sponsored, 3-site study currently in a phase 2 extension study. The earlier clinical studies showed some positive signals, so we are eagerly awaiting final results.

A Brightening Future

I am incredibly excited about this technology and its potential to help patients with MacTel, who up to this point have had no hope for relief. If Neurotech’s NT-501 is approved for use, it will have been proved safe and effective in significantly slowing progression of the disease, adding perhaps years of useful vision for people facing a bleak future of diminishing eyesight.

Although our ECT treatment is designed for MacTel, the technology is highly customizable. It could be a game-changer for patients with a variety of retinal diseases and glaucoma. If we can bring this novel device across the finish line, the goal will be to investigate it for use in other areas of ophthalmology. More developments are sure to follow, and if MacTel is threatening you, your patient, or a loved one, I sincerely believe that hope is on the horizon.

Thomas Aaberg Jr, MD

P: 616-954-2020
Aaberg is chief medical officer at Neurotech Pharmaceuticals. He has no financial disclosures related to this content. He is a retina specialist with Retina Specialists of Michigan, and an assistant clinical professor at Michigan State University in East Lansing.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Kelsey Roelofs, MD, details collaborative strategies for the management of thyroid eye disease
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
© 2024 MJH Life Sciences

All rights reserved.